NCT06601075 The Role of 18F-FDG and 68Ga-FAPI PET/CT in the Diagnosis and the Efficacy Evaluation of Advanced Colorectal Cancer (peritoneal Metastasis With/without Other Metastases)
| NCT ID | NCT06601075 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ruijin Hospital |
| Condition | Advanced Colorectal Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-02-01 |
| Primary Completion | 2026-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2025-02-01 with a primary completion date of 2026-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to investigate the value of 18F-FDG and 68Ga-FAPI PET/CT in evaluating the outcome of conversion therapy and the prognosis of advanced colorectal cancer (peritoneal metastasis with/without other metastases)
Eligibility Criteria
Inclusion Criteria: 1. Histologically confirmed colorectal cancer, clinical or other imaging suspicion of peritoneal metastasis with or without other distant metastases. 2. Patients voluntarily enrolled in this study by signing an informed consent form 3. Age ≥ 18 years 4. Expected life expectancy ≥ 3 months 5. Adequate organ and bone marrow function 6. Willingness to adhere to the study protocol and follow-up programme Exclusion Criteria: 1. Pregnant or breastfeeding women. 2. Patients with a history of other malignant diseases in the last 5 years, except cured skin cancer and carcinoma in situ of cervix 3. Severe mental disease, uncontrolled epilepsy, or central nervous system disease 4. Subjects with current concurrent interstitial pneumonitis or interstitial lung disease, or subjects with previous interstitial pneumonitis or interstitial lung disease requiring hormonal therapy, or subjects with other conditions that may interfere with the judgement and management of immune-related pulmonary toxicity, e.g., pulmonary fibrosis, organising pneumonia (e.g., occlusive bronchiectasis), pulmonary fibrosis, organising pneumonia (e.g., occlusive bronchiectasis), pneumoconiosis, Drug-associated pneumonia, idiopathic pneumonia, active pneumonia, or severe pulmonary impairment on CT; and active tuberculosis
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06601075 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Advanced Colorectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06601075 currently recruiting?
Yes, NCT06601075 is actively recruiting participants. Contact the research team at jiajiahu@shsmu.edu.cn for enrollment information.
Where is the NCT06601075 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06601075 clinical trial?
NCT06601075 is sponsored by Ruijin Hospital. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.